X4 Pharmaceuticals Inc (XFOR) Hedge Fund Ownership (Q1 2026)

Q: Is it too late to buy X4 Pharmaceuticals Inc (XFOR) following the 2026 Q2 hedge fund 13F filings?

As of today, XFOR has moved +0.0% since the 2026 Q2 13F filing date (August 14, 2026), compared to +0.0% for the XLV sector ETF — an outperformance of +0.0%. Since the quarter end (June 30, 2026), XFOR gained -9.6% vs +5.5% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

X4 Pharmaceuticals Inc (XFOR)

78 + Investors. Track Smart Money conviction in XFOR. See who's accumulating, reducing, or initiating positions.

Smart Money Signals — XFOR

Based on 78 hedge funds · latest filing: 2026 Q1 · updated quarterly

📈

Buying streak — 2 quarters in a row

last 6Q

For 2 consecutive quarters, more hedge funds added XFOR than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

🏔️

At the ownership peak (100% of max)

100% of all-time peak

78 hedge funds hold XFOR right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.

🚀

Fast accumulation — +3800% more funds vs a year ago

fund count last 6Q

+76 new funds entered over the past year (+3800% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks.

🟡

Slight buying edge — 53% buying

38 buying34 selling

Last quarter: 38 funds bought or added vs 34 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

⚠️

Fewer new buyers each quarter (-22 vs last Q)

new funds entering per quarter

Funds opening this position for the first time: 49 → 11 → 39 → 17. Each quarter fewer new institutions are entering. This usually means most funds that wanted in are already in — the stock is well-known but the pool of potential new buyers is shrinking.

🔄

Mostly new holders — 69% entered in last year

■ 3% conviction (2yr+) ■ 28% medium ■ 69% new

Only 2 funds (3%) have held >2 years. The majority of current holders are relatively new to the position. New holders tend to sell faster when prices drop — a shallow conviction base that could amplify any sell-off.

➡️

Steady discovery — ~17 new funds/quarter

2 → 49 → 11 → 39 → 17 new funds/Q

New funds entering each quarter: 49 → 11 → 39 → 17. Consistent flow of new institutional buyers without clear acceleration or slowdown.

🌱

Early stage — 96% of holders entered in last year

■ 4% veterans ■ 0% 1-2yr ■ 96% new

Of 78 current holders: 75 (96%) entered in the past year, only 3 (4%) are 2+ year veterans. This is an early-phase institutional idea — still being discovered. High upside potential if the thesis plays out, but thin conviction base.

✅

Strong quality — 26% AUM from major funds

26% from top-100 AUM funds

22 of 78 holders rank in the top 100 by AUM, accounting for 26% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

6.7

out of 10

Moderate Exit Risk

Exit risk score 6.7/10 — some crowding factors present, but no critical concentration. Watch ownership trend over the next 1–2 quarters for direction.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Metric	All 13F Filers (2026 Q1)	Prior (2025 Q4)	Change
Funds Holding	78	74	5.41%
13F Shares	90M	86M	5.06%
Total Value	$374M	$344M	8.53%
New Positions	17	39	-22
Increased Positions	21	17	+4
Closed Positions	13	7	+6
Reduced Positions	21	7	+14
Total Calls	0	1	-100.0%
Total Puts	0	0	-
PUT/CALL Ratio	0.0	0.0	Bullish

Metric

All 13F Filers (2026 Q1)

Prior (2025 Q4)

Change

Funds Holding

5.41%

13F Shares

90M

86M

5.06%

Total Value

$374M

$344M

8.53%

New Positions

-22

Increased Positions

Closed Positions

Reduced Positions

+14

Total Calls

-100.0%

Total Puts

PUT/CALL Ratio

0.0

Bullish

Institutional Holders (2026 Q2)

78 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in XFOR. Verified SEC 13F-HR filings.

QUARTER:

2026 Q2 filings are still coming in. Only funds that have filed so far are shown — top holders may not have reported yet. Full 13F data typically settles by ~50 days after quarter-end.

FILTER:All New Added To Reduced No Change | Overweight >5%

Top 25 XFOR holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
#	Investor	% of Portfolio	Shares	Mkt Value
1	Empery Asset Management, LP	37.43%	6,930,591	$32.4M
2	Kalehua Capital Management LLC	12.46%	3,722,840	$17.4M
3	Rosalind Advisors, Inc.	5.58%	3,214,766	$15.0M
4	Saturn V Capital Management LP	4.67%	6,973,343	$32.6M
5	Caxton Corp	3.92%	15,557	$73K
6	Bain Capital Life Sciences Investors, LLC	2.21%	7,967,454	$37.2M
7	Trails Edge Capital Partners, LP	1.91%	2,571,478	$12.0M
8	Verdad Advisers, LP	1.57%	352,093	$1.6M
9	Perceptive Advisors LLC	0.56%	7,933,491	$37.0M
10	Samsara BioCapital, LLC	0.54%	1,395,587	$6.5M
11	Braidwell LP	0.50%	2,922,754	$13.6M
12	Stonepine Capital Management, LLC	0.49%	224,989	$1.1M
13	Deep Track Capital, LP	0.40%	5,878,757	$27.5M
14	Nantahala Capital Management, LLC	0.38%	2,449,468	$11.4M
15	Venrock Adviser, LLC	0.27%	1,934,253	$9.0M
16	Bvf Inc/Il	0.27%	2,233,742	$10.4M
17	Palumbo Wealth Management LLC	0.07%	67,116	$313K
18	Affinity Asset Advisors, LLC	0.03%	145,000	$677K
19	Woodline Partners LP	0.01%	1,001,095	$4.7M
20	Axq Capital, LP	0.01%	22,880	$107K
21	Pettinga Financial Advisors LLC	0.01%	10,000	$47K
22	Susquehanna Portfolio Strategies, LLC	0.01%	87,282	$408K
23	Caption Management, LLC	0.01%	250,000	$1.2M
24	Indivisible Partners	0.00%	10,000	$47K
25	Morgan Stanley	0.00%	9,461,279	$44.2M

Investor	Ownership History	% of Portfolio	Prev %	Rank	Conviction	Avg Buy Price	13F Score™ 3Y / 7Y	Sell Timing	Shares	Mkt Value	Change	Change %	Source	Quarter	Filed

Frequently Asked Questions — X4 Pharmaceuticals Inc (XFOR)

What does the Smart Money Trend signal show for XFOR?

Buying streak — 2 quarters in a row: For 2 consecutive quarters, more hedge funds added XFOR than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for XFOR?

Slight buying edge — 53% buying: Last quarter: 38 funds bought or added vs 34 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

What is the fund quality score for XFOR holders?

Strong quality — 26% AUM from major funds: 22 of 78 holders rank in the top 100 by AUM, accounting for 26% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

How long have hedge funds held XFOR?

Mostly new holders — 69% entered in last year: Only 2 funds (3%) have held >2 years. The majority of current holders are relatively new to the position. New holders tend to sell faster when prices drop — a shallow conviction base that could amplify any sell-off.

Is it too late to buy X4 Pharmaceuticals Inc (XFOR) following the 2026 Q2 hedge fund 13F filings?

As of today, XFOR has moved +0.0% since the 2026 Q2 13F filing date (August 14, 2026), compared to +0.0% for the XLV sector ETF — an outperformance of +0.0%. Since the quarter end (June 30, 2026), XFOR has gained -9.6% vs +5.5% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Market Cap	--
Enterprise Value	--
Trailing P/E	--
Forward P/E	--
PEG Ratio (5yr expected)	--
Price/Sales (ttm)	--
Price/Book (mrq)	--
Enterprise Value/Revenue	--
Enterprise Value/EBITDA	--
Beta (5Y Monthly)	--
Short Ratio (Days to Cover)	--
Short % of Float	--

Profit Margin	--
Return on Assets (ttm)	--
Return on Equity (ttm)	--

Revenue (ttm)	--
Net Income Avi to Common (ttm)	--
Diluted EPS (ttm)	--
Total Cash (mrq)	--
Total Debt/Equity (mrq)	--
Levered Free Cash Flow (ttm)	--

X4 Pharmaceuticals Inc (XFOR)

Smart Money Signals — XFOR

Buying streak — 2 quarters in a row

At the ownership peak (100% of max)

Fast accumulation — +3800% more funds vs a year ago

Slight buying edge — 53% buying

Fewer new buyers each quarter (-22 vs last Q)

Mostly new holders — 69% entered in last year

Steady discovery — ~17 new funds/quarter

Early stage — 96% of holders entered in last year

Strong quality — 26% AUM from major funds

Institutional Sentiment Summary — XFOR

Hedge Fund Ownership: XFOR

Market Analysis: XFOR

Analyst Price Targets

Analyst Recommendations

Stock Performance

Company Profile: XFOR

Is It Too Late to Buy X4 Pharmaceuticals Inc (XFOR) Based on Hedge Fund 13F Filings?

Hedge Fund Positioning: XFOR

Statistics: XFOR

Valuation Measures Data as of: --

Financial Highlights

Institutional Holders (2026 Q2)

Frequently Asked Questions — X4 Pharmaceuticals Inc (XFOR)

Welcome to 13Foresight!